Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 1/2020

01-02-2020 | Autoimmune Hepatitis | Case Report

A case of primary biliary cholangitis overlapping with type 2 autoimmune hepatitis

Authors: Nozomi Amano, Sho Sato, Ayato Murata, Hironori Tsuzura, Ko Tomishima, Shunsuke Sato, Kohei Matsumoto, Yuji Shimada, Katsuyori Iijima, Kenichi Harada, Takuya Genda

Published in: Clinical Journal of Gastroenterology | Issue 1/2020

Login to get access

Abstract

A 42-year-old woman was admitted to our hospital with cholestatic liver injury. Serological examination revealed anti-mitochondrial M2 antibody positivity and anti-nuclear antibody and anti-smooth muscle antibody negativity. Histological examination of the first liver biopsy revealed chronic nonsuppurative destructive cholangitis with epithelioid granulomas. Ursodeoxycholic acid therapy successfully treated her cholestasis. Sixteen months later, she developed acute icteric hepatitis with elevation of serum aspartate and alanine aminotransferase levels. Anti-mitochondrial M2 positivity and anti-nuclear antibody and anti-smooth muscle antibody negativity persisted at that time. However, it became clear that anti-liver kidney microsomal type 1 antibody was positive. Histological examination of the second liver biopsy demonstrated scarce interface hepatitis and evident parenchymal inflammation and centrilobular zonal necrosis. Her liver biochemical test results promptly improved with the addition of prednisolone therapy. Considering the findings, she was diagnosed with primary biliary cholangitis–type 2 autoimmune hepatitis overlap syndrome. According to a literature review, this is an extremely rare autoimmune overlap syndrome.
Literature
1.
go back to reference Geubel AP, Baggenstoss AH, Summerskill WH. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology. 1976;71:444–9.CrossRef Geubel AP, Baggenstoss AH, Summerskill WH. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology. 1976;71:444–9.CrossRef
2.
go back to reference Klöppel G, Seifert G, Lindner H, et al. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity. Virchows Arch A Pathol Anat Histol. 1977;373:143–60.CrossRef Klöppel G, Seifert G, Lindner H, et al. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity. Virchows Arch A Pathol Anat Histol. 1977;373:143–60.CrossRef
3.
go back to reference Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296–301.CrossRef Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296–301.CrossRef
4.
go back to reference Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis: The intractable hepatobiliary disease study group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res. 2014;44(1):71–90.CrossRef Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis: The intractable hepatobiliary disease study group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res. 2014;44(1):71–90.CrossRef
5.
go back to reference Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with anti-liver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology. 1987;7:1333–9.CrossRef Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with anti-liver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology. 1987;7:1333–9.CrossRef
6.
go back to reference Invernizzi P, Alessio MG, Smyk DS, et al. Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterol. 2012;12:92.CrossRef Invernizzi P, Alessio MG, Smyk DS, et al. Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterol. 2012;12:92.CrossRef
7.
go back to reference Mullin S, Rabah R, Malas S, et al. Autoimmune hepatitis type 2 associated with positive antimitochondrial antibodies: an overlap syndrome? Clin Pediatr (Phila). 2016;55:479–82.CrossRef Mullin S, Rabah R, Malas S, et al. Autoimmune hepatitis type 2 associated with positive antimitochondrial antibodies: an overlap syndrome? Clin Pediatr (Phila). 2016;55:479–82.CrossRef
8.
go back to reference Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.CrossRef Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.CrossRef
9.
go back to reference Lohse AW, zum Büschenfelde KH, Franz B, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology. 1999;29:1078–84.CrossRef Lohse AW, zum Büschenfelde KH, Franz B, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology. 1999;29:1078–84.CrossRef
10.
go back to reference Hofer H, Oesterreicher C, Wrba F, et al. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006;59:246–9.CrossRef Hofer H, Oesterreicher C, Wrba F, et al. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006;59:246–9.CrossRef
11.
go back to reference Nguyen Canh H, Harada K, Ouchi H, et al. Acute presentation of autoimmune hepatitis: a multicenter study with detailed histological evaluation in a large cohort of patients. J Clin Pathol. 2017;70:961–9.CrossRef Nguyen Canh H, Harada K, Ouchi H, et al. Acute presentation of autoimmune hepatitis: a multicenter study with detailed histological evaluation in a large cohort of patients. J Clin Pathol. 2017;70:961–9.CrossRef
12.
go back to reference Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.CrossRef Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.CrossRef
13.
go back to reference Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394–401.CrossRef Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30:394–401.CrossRef
Metadata
Title
A case of primary biliary cholangitis overlapping with type 2 autoimmune hepatitis
Authors
Nozomi Amano
Sho Sato
Ayato Murata
Hironori Tsuzura
Ko Tomishima
Shunsuke Sato
Kohei Matsumoto
Yuji Shimada
Katsuyori Iijima
Kenichi Harada
Takuya Genda
Publication date
01-02-2020
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 1/2020
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-019-01017-2

Other articles of this Issue 1/2020

Clinical Journal of Gastroenterology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine